Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway.
AIM
To validate the utility of Annexin A10 as a surrogate marker of the serrated neoplasia pathway in invasive colorectal cancers (CRCs).


METHODS
A total of 1133 primary CRC patients who underwent surgical resection at Seoul National University Hospital between January 2004 and December 2007 were enrolled. Expression of Annexin A10 was evaluated by immunohistochemistry using tissue microarray and paired to our findings on clinicopathologic and molecular characteristics of each individual. CpG island methylator phenotype was determined by MethyLight assay and microsatellite instability was determined by high performance liquid chromatography. KRAS and BRAF mutation status was evaluated by direct sequencing and allele-specific PCR. Univariate and stage-specific survival analyses were performed to reveal the prognostic value of Annexin A10 expression.


RESULTS
Annexin A10 expression was observed in 66 (5.8%) of the 1133 patients. Annexin A10 expression was more commonly found in females and was associated with proximal location, ulcerative gross type, advanced T category, N category and TNM stage. CRCs with Annexin A10 expression showed an absence of luminal necrosis, luminal serration and mucin production. CRCs with Annexin A10 expression were associated with CpG island methylator phenotype, microsatellite instability and BRAF mutation. In survival analysis, Annexin A10 expression was associated with poor overall survival and progression-free survival, especially in stage IV CRCs.


CONCLUSION
Annexin A10 expression is associated with poor clinical behavior and can be used a supportive surrogate marker of the serrated neoplasia pathway in invasive CRCs.
['Bae|Jeong Mo|JM|', 'Kim|Jung Ho|JH|', 'Rhee|Ye-Young|YY|', 'Cho|Nam-Yun|NY|', 'Kim|Tae-You|TY|', 'Kang|Gyeong Hoon|GH|']
D000368:Aged D017302:Annexins D014408:Biomarkers, Tumor D015179:Colorectal Neoplasms D018899:CpG Islands D019175:DNA Methylation D004252:DNA Mutational Analysis D018572:Disease-Free Survival D005260:Female D006785:Hospitals, University D006801:Humans D007150:Immunohistochemistry D053208:Kaplan-Meier Estimate D008297:Male D053842:Microsatellite Instability D008875:Middle Aged D009154:Mutation D009361:Neoplasm Invasiveness D009367:Neoplasm Staging D011237:Predictive Value of Tests D016016:Proportional Hazards Models D048493:Proto-Oncogene Proteins B-raf D016283:Proto-Oncogene Proteins p21(ras) D015203:Reproducibility of Results D056910:Republic of Korea D012189:Retrospective Studies D012307:Risk Factors D046888:Tissue Array Analysis D016896:Treatment Outcome
Annexin A10 Colorectal cancer Serrated neoplasia pathway CpG island methylator phenotype BRAF mutation